A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

NCT03607513 | Completed Phase 1

• 3 other identifiers: CR1084572018-000428-3264264681EDI1003
• Study Type: interventional
• Target: 105
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JNJ-64264681 in healthy participants after single and multiple oral doses.

Conditions

Healthy

Outcome Measures

Primary Outcomes (16)

• Single Ascending Dose (SAD): Number of Participants with Adverse Events

  An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

  Up to Day 14

• Multiple Ascending Dose (MAD): Number of Participants with Adverse Events

  An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

  Up to Day 24

• SAD: Maximum Observed Plasma Concentration (Cmax)

  Cmax is the maximum observed plasma JNJ-64264681 concentration.

  Up to Day 4

• MAD: Maximum Observed Plasma Concentration (Cmax)

  Cmax is the maximum observed plasma JNJ-64264681 concentration.

  Up to Day 13

• SAD: Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Tmax is defined as actual sampling time to reach maximum observed concentration.

  Up to Day 4

• MAD: Time to Reach Maximum Observed Plasma Concentration (Tmax)

  Tmax is defined as actual sampling time to reach maximum observed concentration.

  Up to Day 13

• SAD: Time to Last Quantifiable Plasma Concentration (Tlast)

  The Tlast is the time to last observed quantifiable plasma concentration.

  Up to Day 4

• MAD: Time to Last Quantifiable Plasma Concentration (Tlast)

  The Tlast is the time to last observed quantifiable plasma concentration.

  Up to Day 13

• SAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24])

  AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours.

  Day 1: Up to 24 hours post-dose

• MAD: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24])

  AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours.

  Day 1: Up to 24 hours post-dose

• SAD: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Observed Quantifiable Concentration (AUClast)

  AUClast is defined as area under the plasma JNJ-64264681 concentration-time curve from time 0 to time of the last observed quantifiable concentration.

  Up to Day 4

• MAD: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

  AUCtau is area under the plasma JNJ-64264681 concentration-time curve during a dosing interval (tau) at steady-state.

  Day 10

• SAD: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

  The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

  Up to Day 3

• SAD: Apparent Elimination Half-life (t1/2)

  t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve.

  Up to Day 3

• MAD: Apparent Elimination Half-life (t1/2)

  t1/2 is apparent elimination half-life of JNJ-64264681 associated with the terminal slope (z) of the semi-logarithmic drug concentration-time curve.

  Up to Day 13

• MAD: Accumulation Ratio

  MAD: Accumulation Ratio obtained by dividing AUC of JNJ-64264681 at two different time points.

  Up to Day 13

Study Arms (2)

Single Ascending Dose (SAD)

EXPERIMENTAL

The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.

Drug: JNJ-64264681; Drug: Placebo

Multiple Ascending Dose (MAD)

EXPERIMENTAL

The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.

Drug: JNJ-64264681; Drug: Placebo

Interventions

JNJ-64264681 DRUG

For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.

Multiple Ascending Dose (MAD); Single Ascending Dose (SAD)

Placebo DRUG

Matching placebo to JNJ-64264681 will be administered as oral solution.

Multiple Ascending Dose (MAD); Single Ascending Dose (SAD)

Eligibility Criteria

• Age: 18 Years - 58 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participant must have a body mass index (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m\^2) (BMI = weight\[kg\]/height\[m\]\^2), and a body weight of not less than 50 kilogram (kg)
• Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12-lead Electrocardiogram (ECG) performed at screening and Day -1
• Participant must be healthy on the basis of clinical laboratory tests performed at screening and Day -1. If the results of the serum chemistry panel, coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
• Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
• Female participants must not be of childbearing potential by fulfilling 1 of the criteria below: a) Be over 45 years of age with no menses for 12 months without an alternative medical cause, with screening follicle stimulating hormone (FSH) levels of greater than (\>)40 International Units Per Liter (IU/L) or milli-international units per milliliter (mIU/mL). b) Be permanently surgically sterile. Permanent surgical sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy. Documentation of FSH levels is not required in the case of surgical sterility

You may not qualify if:

• Participant has current, or history of clinically significant medical illness including, but not limited to, liver or renal insufficiency, significant cardiac (including heart valve disease), vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Participant has a history of abnormal bleeding or bruising
• Participant has a history of atrial fibrillation or history of arrhythmias
• Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence)
• Participant has known allergies, hypersensitivity, or intolerance to polyethylene glycol 400 (PEG400) (vehicle for JNJ-64264681 for oral solution dosing) for participant in a cohort where study drug is to be dosed as an oral solution, or to microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, silica dioxide, sodium lauryl sulfate, magnesium stearate, or gelatin (excipients in the solid dose formulation (capsule) of JNJ-64264681) for participant in a solid dose formulation cohort

Sponsors & Collaborators

• Janssen Research & Development, LLC: lead

Study Sites (1)

Clinical Pharmacology Unit

Merksem, 2170, Belgium

Location

MeSH Terms

Interventions

JNJ-64264681

Study Officials

• Janssen Research & Development, LLC Clinical Trial

  Janssen Research & Development, LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2018
• First Posted: July 31, 2018
• Study Start: July 31, 2018
• Primary Completion: August 9, 2019
• Study Completion: August 9, 2019
• Last Updated: February 3, 2025

Record last verified: 2025-01

Locations

BE (1)